Published in Gastroenterology on January 01, 2003
Prospective Observational Study of Disease Progression in Chronic Hepatitis C | NCT02011932
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol (2014) 2.39
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Steatosis in chronic hepatitis C: why does it really matter? Gut (2006) 2.10
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut (2007) 1.58
Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology (2009) 1.40
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol (2009) 1.17
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun (2015) 1.14
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut (2003) 1.11
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology (2011) 1.07
The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother (2015) 1.07
Fibrosis progression in chronic hepatitis C virus infection. Gut (2004) 1.02
Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. J Virol (2013) 0.97
Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther (2016) 0.97
Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Dig Dis Sci (2011) 0.94
A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut (2007) 0.91
Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One (2014) 0.90
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol (2010) 0.90
Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection: A 15-Year Prospective Study. Medicine (Baltimore) (2013) 0.90
p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res (2012) 0.88
The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS (2008) 0.87
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol (2014) 0.86
Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon (2011) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol (2012) 0.85
Hepatic Inflammation May Influence Liver Stiffness Measurements By Transient Elastography in Children and Young Adults. J Pediatr Gastroenterol Nutr (2016) 0.84
Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression. Aliment Pharmacol Ther (2014) 0.84
Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci (2009) 0.83
Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis (2008) 0.83
Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology (2012) 0.82
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol (2015) 0.81
Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology (2015) 0.80
Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. J Gastroenterol (2009) 0.80
Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis (2010) 0.80
Pathological evolution of hepatitis C virus-"Healthy carriers". World J Gastroenterol (2008) 0.80
Inflammatory response of endothelial cells to hepatitis C virus recombinant envelope glycoprotein 2 protein exposure. Mem Inst Oswaldo Cruz (2014) 0.80
The 2013 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infect Chemother (2013) 0.79
Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol (2016) 0.79
Serum complement C4a and its relation to liver fibrosis in children with chronic hepatitis C. World J Hepatol (2013) 0.79
Prognostic factors for progression of liver structural lesions in chronic hepatitis C patients. World J Gastroenterol (2008) 0.79
Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS One (2015) 0.79
Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterol Hepatol (N Y) (2006) 0.78
Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. AIDS Patient Care STDS (2009) 0.78
Impact of rural residence and health system structure on quality of liver care. PLoS One (2013) 0.78
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma. Liver Cancer (2013) 0.78
Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects. Ann Saudi Med (2009) 0.78
Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci (2005) 0.77
Clinical Advancements in the Targeted Therapies against Liver Fibrosis. Mediators Inflamm (2016) 0.77
Plasma sphingolipids as potential indicators of hepatic necroinflammation in patients with chronic hepatitis C and normal alanine aminotransferase level. PLoS One (2014) 0.77
Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? World J Gastroenterol (2010) 0.77
Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. Open Forum Infect Dis (2016) 0.77
Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C. J Clin Transl Hepatol (2014) 0.76
Distinct features in natural history and outcomes of acute hepatitis C. J Clin Gastroenterol (2015) 0.76
Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol (2007) 0.76
Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue. Res Nurs Health (2010) 0.75
Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. J Clin Gastroenterol (2013) 0.75
HIV-HCV Coinfection. Gastroenterol Hepatol (N Y) (2006) 0.75
Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J Viral Hepat (2016) 0.75
On beyond staging and grading: Liver biopsy evaluation in a posttreatment world. Hepatology (2017) 0.75
Up-regulation of Plasma Hexosylceramide (d18: 1/18: 1) Contributes to Genotype 2 Virus Replication in Chronic Hepatitis C: A 20-Year Cohort Study. Medicine (Baltimore) (2016) 0.75
The molecular prevalence of viral infections in transplant candidates with bone marrow suppression, shiraz, southern iran, 2010. Int J Organ Transplant Med (2013) 0.75
Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. J Infect Dis (2016) 0.75
Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol (2017) 0.75
CXCL9-11 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. Clin Transl Med (2017) 0.75
Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels. J Gastroenterol (2008) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science (2014) 5.47
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (2011) 3.46
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nat Med (2013) 3.24
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Gastrointestinal involvement in chronic granulomatous disease. Pediatrics (2004) 2.80
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 2.78
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology (2004) 2.64
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology (2011) 2.39
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol (2005) 2.33
Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology (2011) 2.33
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology (2013) 2.17
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 2.08
Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. Transplantation (2005) 2.08
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch (2007) 1.91
Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology (2003) 1.91
The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol (2003) 1.90
The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology (2006) 1.89
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology (2007) 1.81
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology (2013) 1.78
Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood (2004) 1.77
Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science (2008) 1.77
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis (2003) 1.76
Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology (2013) 1.76
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther (2004) 1.72